New York, Sept. 13 - Anthera Pharmaceuticals closed a $36 million round of venture financing.
Proceeds will be used to start clinical development of Anthera's portfolio of anti-inflammatory compounds licensed from Eli Lilly and Co. and Shionogi & Co., Ltd.
Its secretory phospholipase programs are preparing for phase 2 clinical testing in multiple indications.
Later this year, Anthera plans to start clinical studies for the program's lead compound A-001 as an early intervention therapy for acute chest syndrome in patients with underlying sickle cell disease, something it called a $500 million worldwide market opportunity.
VantagePoint Venture Partners and Sofinnova Ventures were joint lead investors and the round also included Pappas Ventures and Mitsubishi International Corp. along with series A-1 investors Sears Capital Management and SIM Equity. Eli Lilly and Shionogi also received equity under the license agreement.
Annette Bianchi, managing director and co-head of VantagePoint's healthcare practice group and Jim Healy, general partner of Sofinnova Ventures were named to the board.
Anthera is a San Francisco-based pharmaceutical development company.
| Issuer: | Anthera Pharmaceuticals
|
| Issue: | Venture financing
|
| Amount: | $36 million
|
| Investors: | VantagePoint Venture Partners and Sofinnova Ventures (leads), Pappas Ventures, Mitsubishi International Corp., Sears Capital Management, SIM Equity
|
| Announcement date: | Sept. 13
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
